The title of the application published this week, "Graphene-Based FET Diagnostic Sensor Devices," points at a sensor chip; the independent claims tell you exactly which parts of that chip the applicant is trying to fence off. The hero record, US20260177523A1, published June 25, 2026, is directed to a graphene field-effect-transistor sensor array engineered for the label-free, multiplex readout of target nucleic acids in a fluid sample. Two things are worth separating immediately: what the device is, and what the claims actually recite about it. The device is an array of independent transistor-based sensors in a sealed housing. The claims, read closely, are built around how a nucleic-acid probe is fastened to the graphene, and that attachment chemistry is where the independent-claim scope lives.

Claim 1 opens, verbatim, with the device skeleton: "A graphene-based multiplex diagnostic device comprising: a sealable housing; an inlet configured to receive a biological fluid; a graphene-based FET sensor array within the sealable housing and communicatively coupled to the inlet to receive the biological fluid." From there the limitations narrow to the per-sensor build: each independent sensor comprises a graphene field-effect transistor with a graphene monolayer, a nucleic-acid probe "for hybridizing and detecting a target nucleic acid," and at least one blocking agent. The limitation that gives claim 1 its shape is the attachment recipe: "the graphene monolayer is functionalized with a linker for immobilizing the nucleic acid probe to the graphene monolayer; and wherein the nucleic acid probe is terminally functionalized to bind to the linker." In plain terms, claim 1 covers the linker-mediated version of the chip, the one where a chemical bridge is laid down on the graphene and the probe is built to clip onto that bridge.

This disclosure generally relates to graphene-based diagnostic sensor devices. More particularly, the disclosure relates to graphene-based diagnostic sensor devices for the multiplex detection of target nucleic acids in fluid samples, including biological fluid samples. In certain aspects, the graphene-based multiplex diagnostic devices disclosed herein comprise a graphene-based FET multiplex sensor array having multiple independent sensors, each having a nucleic acid probe, for hybridizing and detecting a target nucleic acid, attached to a graphene monolayer.— Graphene-Based FET Diagnostic Sensor Devices, US20260177523A1

The application does not stop at one independent claim. Claim 12 recites the same device skeleton, the sealable housing, inlet, and array of independent graphene-FET sensors, but swaps out the attachment limitation entirely. Instead of a linker, claim 12 recites that "the nucleic acid probe is a polycyclic aromatic hydrocarbon modified nucleic acid probe," and its dependent claims make the mechanism explicit: the probe "binds directly to the graphene monolayer via pi-pi stacking" (claim 13), with pyrene named as the polycyclic aromatic hydrocarbon (claim 14). Two independent claims, two attachment strategies. Claim 1 fences the linker-immobilized embodiment; claim 12 fences the linker-free embodiment where an aromatic anchor on the probe stacks flat against the graphene by the same pi-pi interaction that holds graphite sheets together. Reading the two side by side, the applicant has drafted around both ways of getting a single-stranded DNA probe to sit on a graphene monolayer, which is the engineering choice the whole sensor turns on.

Why the attachment chemistry is the claim, not the transistor

A graphene field-effect transistor senses by electrostatics: target binding at the graphene surface shifts the channel's conductance, so the device reports a hybridization event as an electrical change rather than an optical one. That is what "label-free" means here, no fluorescent or enzymatic tag is recited; the readout is the transistor's response. But a bare graphene monolayer is a generic transducer. What makes one sensor specific to one target, and the next sensor specific to another, is the probe and how cleanly it is anchored. The dependent claims spell out the engineering around that anchoring. Claim 2 recites the probe as a synthetic DNA terminally functionalized with an amine or thiol group. Claim 3 enumerates the linker options, a list that includes 1-pyrenebutyric acid succinimidyl ester and several PEG-based linkers. Claims 4 and 5 recite blocking agents, methoxypolyethylene glycol pyrene, Tween 20, polyvinyl alcohol, and others, whose job is to passivate the graphene and the linker so that nothing but a genuine hybridization event moves the signal. The blocking-agent limitations matter because on a sensor this sensitive, non-specific adsorption is noise, and the claims treat passivation as part of the invention rather than an afterthought.

Scale is also recited. Claim 6 is directed to an array "for the simultaneous detection of between 20 to 30 different target nucleic acids," and the specification describes an example layout of 98 sensors wired to a common source and gate with independent drains, grouped so a reader can interrogate them simultaneously or in blocks. That is the multiplex part: many independent FET channels on one chip, each functionalized with a different probe, read in parallel from a single fluid inlet. The claim set thus covers a device whose distinguishing features are the probe-to-graphene attachment chemistry, the passivation scheme, and the per-channel multiplex architecture, rather than the graphene transistor as a generic component.

Where the application lands in the patent landscape

The classification matches the claims. The hero record's main CPC is G01N 27/4145, the subgroup for chemically sensitive field-effect transistors, ChemFET-style devices that report a chemical or biological binding event as a transistor response. That is precisely the device claim 1 and claim 12 are directed to: not an optical assay, not a generic biosensor, but a FET whose gate behavior is the measurement. Sitting in G01N 27/4145 places the application in the electrochemical-and-FET sensing neighborhood of the diagnostic-device landscape, distinct from the optical-readout and amplification-based detection families that occupy adjacent G01N and C12Q territory.

On assignee, the record is candid by its silence: the publication carries no assignee entry, which on a published application typically indicates the filing stands in the name of individual applicants rather than a corporate assignee, or that no assignment had been recorded at publication. The brief reports that as the record shows it, an unassigned or individually filed application, and draws no inference about ownership beyond what is on the face of the publication.

The June 25 publication window carries a cluster of related diagnostic-device filings worth deep-linking for context, though they are independent records rather than companions to a single estate. US20260177549A1 ("Methods, Diagnostic Instruments, and Kits for Detecting Diseases") is directed to instruments and kits for detecting an analyte in a sample. US20260176695A1 is directed to a transcriptomic-signature method and kit built around an empirically derived algorithm. US20260174336A1 ("Intraoperative Probe") is directed to a hand-held device that fuses Raman spectroscopy and shear-wave elastography with real-time machine-learning analysis at a common focal point. US20260174571A1 ("Diagnostic Metamaterial Cardiovascular Stent") is directed to a stent built from an active mechanical metamaterial whose conductive components induce contact electrification through a lattice of snapping semicircular segments. Read alongside the graphene-FET chip, the cluster maps a slice of this week's diagnostic-device drop, each anchored in its own independent claims.

The status of these records is the point a claims reading has to hold in view. They are published applications, not granted patents, which is why each resolves to a publications record. Publication means the disclosed scope has entered the public file and is now readable; it does not mean any claim has issued. The two independent claims of US20260177523A1 describe what the applicant is currently seeking, the linker-immobilized and the pi-pi-stacked versions of a multiplex graphene-FET sensor chip, and whatever issues may be narrower as examination works through the limitations. Reading the application tells you what has been put on file and how it is classified; it does not tell you what can be enforced, and this brief makes no judgment on the scope, breadth, or value of any claim. What the record does establish, plainly, is a device architecture, a graphene-FET array, two routes for fastening nucleic-acid probes to it, and a passivation-and-multiplex scheme, now readable in the public file as a pending application in the G01N 27/4145 class.